Biotechnology

Advances of Qilu Pharmaceutical’s QL1706 in Clinical Research Presented at ASCO Annual Meeting

by

JINAN, China, May 31, 2023 /PRNewswire/ — The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session. Two of the posters focus on the latest clinical research progress of Qilu … Read more

Blue Lake Biotechnology to Be Featured at the Biotechnology Innovation Organization (BIO) International Convention

by

ATHENS, Ga. and LOS GATOS, Calif., May 31, 2023 /PRNewswire/ — Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company harnessing the full breadth of the immune system to protect against serious infectious diseases, announced today that company CEO Biao He, Ph.D., will present and host one-on-one partnering meetings at the 2023 Biotechnology Innovation Organization International … Read more

The Caris Precision Oncology Alliance Welcomes Leading Cancer Center

by

Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine IRVING, Texas, May 31, 2023 /PRNewswire/ — Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Memorial Sloan Kettering Cancer Center (MSK), one … Read more

Neogen® to Participate in the 43rd Annual William Blair Growth Stock Conference

by

LANSING, Mich., May 30, 2023 /PRNewswire/ — Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023. John Adent, Neogen’s President and Chief Executive Officer, will present at 4:00 p.m. Central Time. Presentation materials will be posted … Read more

Sector to Reach $38.2 Billion by 2032 at an 8.4% CAGR

by

DUBLIN, May 30, 2023 /PRNewswire/ — The “Global Cell-Based Assay Market – A Global and Regional Analysis: Focus on Product, Services, Application, End User, Technology, Regional Analysis, and Competitive Landscape – Analysis and Forecast, 2023-2032” report has been added to  ResearchAndMarkets.com’s offering. The global cell-based assay market is expected to reach $38.23 billion in 2032 from … Read more

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA – English USA – English

by

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in … Read more

Se otorga la cuarta aprobación IDE de Concept Medical para el balón recubierto de sirolimus MagicTouch para el tratamiento de la enfermedad de la arteria femoral superficial (SFA) USA – español USA – English USA – English USA – Deutsch

by

TAMPA, Fla., 30 de mayo de 2023 /PRNewswire/ — El 24 de mayo de 2023, la FDA de EE.UU. otorgó una exención de dispositivo de investigación (IDE) para el balón recubierto de sirolimus (SCB) MagicTouch PTA de Concept Medical Inc para el tratamiento de las arterias femorales superficiales (SFA). Esto marca la cuarta aprobación de IDE para el balón … Read more

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

by

TAMPA, Fla., May 29, 2023 /PRNewswire/ — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s Sirolimus Coated Balloon (SCB) MagicTouch  PTA for the treatment of Superficial Femoral Arteries (SFA). This marks the fourth IDE approval for the Company’s Sirolimus coated balloon. The Company has … Read more

Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency

by

SAN DIEGO, May 29, 2023 /PRNewswire/ — Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders announced the award of a Fast Track Phase I/II STTR grant from the NIH-NIAMS. This highly competitive grant will provide substantial funding for the advancement of AMP-201, an AAV-ColQ gene … Read more

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

by

OSAKA, Japan, May 29, 2023 /PRNewswire/ — RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus. Collaborators also reported that S/F-iTregs generated … Read more